Explore every episode of the podcast OutSmart Cancer - Precision Oncology. Less Guess Work. More Life!
Dive into the complete episode list for OutSmart Cancer - Precision Oncology. Less Guess Work. More Life!. Each episode is cataloged with detailed descriptions, making it easy to find and explore specific topics. Keep track of all episodes from your favorite podcast and never miss a moment of insightful content.
Rows per page:
50
1–50 of 97
Title
Pub. Date
Duration
40% of Cancers Are Preventable — Here’s What That Means | Dr. Dino Prato
10 avr. 2026
00:10:53
Six hundred thousand Americans will die from cancer this year, but many of these deaths are preventable.
Dr. Prato highlights that early detection and new approaches to cancer prevention could drastically improve outcomes and reduce mortality. We explore the importance of holistic health and effective treatment strategies in oncology to ensure fewer lives are lost to this disease.
🎯 What You’ll Learn in This Episode • What the “40% of cancers are preventable” statistic means • Key lifestyle and environmental risk factors • The role of infections in cancer risk • Why early detection improves outcomes • What multi-cancer early detection (MCED) tests are • How metabolic and immune health influence cancer risk • The difference between prevention and treatment strategies • Why individualized approaches are becoming more important
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“Prevention and early detection may change the trajectory of cancer care.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
A new device has received food and drug administration approval for pancreatic cancer, offering a new tool in cancer treatment.
This wearable technology works by disrupting cancer cells, potentially slowing growth. While not a cure, this development in medical research provides a valuable addition to oncology strategies, buying time for patients.
🎯 What You’ll Learn in This Episode • What Tumor Treating Fields actually are • How the Optune device works • Why pancreatic cancer is difficult to treat • Why slowing tumor division may buy valuable treatment time • The limitations of IV chemotherapy delivery to pancreatic tumors • Why immune activation is critical for long-term response • How multi-omics testing identifies personalized targets • Why new technologies should be combined with precision strategies
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“New technology can slow cancer — but long-term control often depends on activating the immune system.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Why Viral Cancer Cure Claims Spread So Fast (And Why You Should Be Skeptical)
08 avr. 2026
00:13:30
In early 2026, social media buzzed with claims of a 100% success rate for free cancer vaccines, raising hopes for patients eager for a medical breakthrough.
This news highlights how cancer treatment can become a tool in geopolitics and global politics, as nations vie for influence. It's crucial to understand these social media trends and approach such information with critical thinking.
🎯 What You’ll Learn in This Episode • Why viral “100% cure” headlines spread so quickly online • The difference between early research and clinical treatment • How cancer vaccines and mRNA therapies are being studied • Why cancer remains biologically complex and individualized • What multi-omics testing means in oncology • Why tumor genetics and immune markers matter • How precision oncology evaluates treatment options • Why patients should evaluate headlines carefully before making treatment decisions
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“Cancer headlines move fast — but treatment decisions should always be guided by data.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Peptides & Cancer — The Dangerous Ones You Must Avoid | Dr. Dino Prato
07 avr. 2026
00:16:18
Dr. Prato explores the promising field of peptide therapy, highlighting how these powerful compounds can contribute to healthy aging and overall wellness.
We discuss the potential for peptides to support joint health and bone health, offering a new perspective on maintaining physical vitality. The research also suggests benefits for brain health, making peptides a fascinating area of study for those interested in anti-aging strategies.
🎯 What You’ll Learn in This Episode: - What peptides actually are - Why timing matters during chemotherapy - Which peptides may stimulate growth pathways - Which peptides may support immune signaling - The risks of black-market peptide sourcing - Why diet, sleep, and gut health come first - How precision oncology integrates immune support safely - The importance of physician supervision
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“Peptides don’t heal chaos — they amplify signals. Make sure the signal is the right one.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Bioidentical Hormones, Circulation, and Rebuilding Intimacy Post-Cancer
06 avr. 2026
00:17:11
Cancer treatment can profoundly affect intimacy and marital connection, often leading to challenges in sexual health and relationships. Many couples face issues like decreased sexual function and confidence after chemotherapy, yet these challenges are not insurmountable.
Dr. Prato provides practical marriage advice and integrative tools to help navigate these impacts, offering hope and solutions for a fulfilling connection post-treatment.
🎯 What You’ll Learn in This Episode: - Why cancer treatment affects libido and performance - The role of sleep and cortisol in sexual health - When bioidentical hormones may be appropriate - Safe considerations for testosterone microdosing - When localized estriol therapy may be considered - The role of circulation in erectile function - Natural nitric oxide support strategies - Why emotional connection matters just as much as biology
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“Intimacy is not lost after cancer — it must be rebuilt with wisdom, patience, and the right support.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Cancer Survival Rates Exposed: What American Cancer Society Isn’t Telling You
03 avr. 2026
00:13:32
When a loved one faces metastatic cancer, the outlook can be challenging, with significantly low survival rates for conditions like lung cancer and breast cancer.
Dr. Prato highlights the stark reality of cancer cells spreading, contrasting the American Cancer Society's optimistic 70% overall survival rate with the grim statistics for a cancer patient with advanced disease. Understanding the nuances of cancer treatment and its efficacy against metastasis is crucial.
🎯 What You’ll Learn in This Episode • What the “70% cancer survival” statistic actually represents • Why early-stage and metastatic cancers have very different outcomes • Why stage-specific survival data matters for patients • How early detection dramatically improves outcomes • What multi-cancer early detection testing is • How multi-omics testing helps guide treatment decisions • The role of immune profiling in cancer treatment strategies • Why personalized oncology approaches are growing in importance
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“Cancer statistics describe populations — but treatment decisions must focus on the individual.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Mold Toxins: Why Most Cancer Treatments Fail Without Addressing This
02 avr. 2026
00:10:50
Many cancer patients face a dual challenge: battling the tumor and an invisible enemy—infections from mold and mycotoxins.
Dr. Prato explores how water-damaged buildings can harbor toxic mold, often overlooked by standard oncology practices. We highlight the critical need to address environmental health factors like mold exposure as potential root causes, ensuring comprehensive patient care alongside traditional cancer treatment.
🎯 What You’ll Learn in This Episode: - The difference between mold spores and mycotoxins - How mold exposure can stress the immune system - What CIRS (chronic inflammatory response syndrome) means - Why inflammation complicates cancer recovery - The role of binders and detox support (under medical care) - What MARCoNS biofilm infections are - Why immune balance (TH1/TH2) matters - The right questions to ask about mold testing
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“You can’t rebuild immunity while something is quietly breaking it.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Pancreatic Cancer Breakthrough | How Multi-Target Strategy Stops Tumors Dead
01 avr. 2026
00:09:51
A Spanish research team achieved remarkable results, making pancreatic cancer tumors disappear in mice by targeting multiple escape routes simultaneously. This approach prevented tumor recurrence and resistance, highlighting a design strategy central to precision cancer medicine.
Dr. Dino Prato discusses how this mirrors the principles of targeted cancer therapy, emphasizing the importance of understanding the tumor microenvironment for effective cancer care.
🎯 What You’ll Learn in This Episode: - Why pancreatic cancer is so difficult to treat - What KRAS, EGFR, and STAT3 do - How tumors develop resistance - What the triple-lock strategy means - Why mouse data doesn’t always translate to humans - The difference between one-size-fits-all and precision oncology - Why immune activation matters for long-term control - Questions to ask your doctor about pathway targeting
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“Cancer adapts — so treatment must adapt faster.”
Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied
Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
The Methylene Blue Secret: Starving Cancer, Fueling Life
31 mars 2026
00:15:51
Many people don't consider that cancer might be a 'power plant problem' rather than just a tumor issue.
Dr. Prato explores how mitochondrial damage and its impact on energy production can lead to symptoms like fatigue, brain fog, and immune weakness. Understanding cellular health and metabolic health is crucial, as mitochondrial dysfunction can be a key driver of various diseases, including chronic fatigue syndrome.
🎯 What You’ll Learn in This Episode: - Why mitochondria matter in cancer biology - The link between metabolism and immune function - How toxins and infections damage mitochondrial DNA - What methylene blue does in the electron transport chain - Why timing matters during chemotherapy - The role of CoQ10, NADH, and D-ribose in ATP production - How to support detox and redox balance - Why mitochondrial health influences long-term remission
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“Energy isn’t just about feeling good — it’s about cellular survival.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Cancer Treatment Starts In Your Kitchen | Dr. Dino Prato's Food Protocol
30 mars 2026
00:12:34
Dr. Dino Prato discusses the crucial role of nutrition in cancer treatment, emphasizing that a truly healthy eating approach goes beyond just adding superfoods.
He highlights the importance of removing foods that sabotage the immune system, explaining how this strategy is foundational to effective cancer treatment. Understanding "food as medicine" is key to supporting the body's defenses and acting as an immune system booster.
🎯 What You’ll Learn in This Episode: - The first foods to eliminate from an anti-cancer diet - Why gut microbiome health is critical - How fatty fish and olive oil reduce inflammation - The immune role of beta-glucans from mushrooms - Why cruciferous vegetables support detoxification - The benefits of berries and polyphenols - How green tea (EGCG) supports immune balance - Why sustainable Mediterranean-style eating works long-term
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“Cancer care isn’t just about killing cells — it’s about strengthening the terrain.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Georgia Bill Will Allow OTC Ivermectin | Here’s What Cancer Researchers Actually Know
27 mars 2026
00:12:36
A new Georgia bill allowing over-the-counter ivermectin has ignited debate about medical ethics and individual freedom of choice. This news highlights a deeper concern: cancer treatment options for patients who feel they have no alternatives.
We explore the implications for public health and medicine when patients seek solutions outside conventional care.
🎯 What You’ll Learn in This Episode • What Georgia’s ivermectin bill actually proposes • Why ivermectin is being discussed in cancer research • Why ivermectin is not an FDA-approved cancer treatment • The risks of self-medicating with repurposed drugs • How pathways like PI3K, mTOR, and STAT3 relate to tumor biology • Why repurposed drugs must be target-driven • The role of combination therapy in oncology • How precision oncology evaluates off-label treatments safely
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“The right drug, the right target, the right time — that’s precision oncology.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
The 5 Immune Pillars That Stop Cancer Before It Starts
26 mars 2026
00:18:28
Drawing from 25 years of clinical experience, Dr. Prato discusses methods to greatly reduce cancer risk and how to prevent cancer.
This video highlights the importance of choosing a good doctor and understanding effective cancer care strategies. We emphasize that prevent cancer is a goal we strive for with every patient at our medical clinic.
🎯 What You’ll Learn in This Episode: - Why immunity is the first and last defense against cancer - The 5 foundational pillars of immune resilience - How metabolic dysfunction increases cancer risk - The importance of vitamin D, zinc, and beta-glucans - Why gut health influences 70% of immunity - What multi-cancer early detection testing is - How to approach early signals without panic - The difference between standard screening and precision screening
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“Prevention isn’t luck — it’s preparation.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Your Doctor Will Miss Aggressive Cancer, Here Is Why
25 mars 2026
00:11:18
Some cancers can progress rapidly, even in weeks, often outpacing conventional drug treatments. This video highlights the critical need for proper testing and targeted cancer therapy to address these aggressive forms of cancer. We explore how gene mutations, specifically dna amplification, can accelerate cancer growth and adaptation, emphasizing the role of precision medicine in developing effective cancer treatment strategies.
🎯 What You’ll Learn in This Episode: - What chromothripsis is and why it matters - How gene copy amplification accelerates cancer growth - Why some cancers adapt rapidly to treatment - The link between inflammation and resistance - How immune suppression enables aggressive tumors - Why standard testing may miss key drivers - The role of RNA transcriptomics and spatial biology - The right questions to ask about deep cancer testing
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“Fast-growing cancer isn’t always stronger — it’s often smarter. And smart problems require precision solutions.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
The Real Reason Cancer Comes Back Even After Remission
24 mars 2026
00:09:06
Cancer recurrence often stems from dormant cancer cells, not just the primary tumor. These "sleeper cells" can reawaken years later, leading to metastasis.
This video presents a smarter approach to cancer treatment, focusing on preventing recurrence after remission using off-label drugs and integrative agents.
🎯 What You’ll Learn in This Episode: - Why cancer recurrence often begins with dormant cells - What micrometastatic disease means - How mTOR fuels cancer regrowth - How autophagy helps cancer survive under stress - The role of off-label repurposed medications - Natural compounds that influence growth pathways - Why zinc and vitamin D matter for immune function - The right questions to ask your doctor after remission
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“Remission is not the end of treatment — it’s the beginning of prevention.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Moderna mRNA Cancer Vaccine Shows Promise—But There's a Catch Nobody's Talking About
23 mars 2026
00:14:21
Moderna — the company that became a household name during the global pandemic — is now attacking cancer treatment with personalized mRNA technology in the form of a melanoma immunotherapy vaccine. But does their research hold up?
🎯 What You’ll Learn in This Episode: - What Moderna’s mRNA melanoma vaccine does - How neoantigen vaccines are created - Why Keytruda is used in combination - What a 49% recurrence reduction actually means - The role of tumor heterogeneity - Why cold vs hot tumors matter - How tumor microenvironment impacts response - Differences between synthetic vaccines and direct tumor immunotherapy
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“The future of cancer care isn’t one-size-fits-all — it’s immune-informed precision.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
The Stromal Barrier Problem: Why Chemo Fails for Pancreatic Cancer (And What Works)
05 mars 2026
00:14:15
Pancreatic cancer is one of the toughest cancers in the world — not just because of its location, but because of the stromal barriers that block chemotherapy from reaching the tumor. Most IV chemo delivers less than 1% of the drug to the cancer itself. The result: months of toxicity with very little benefit.
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, explains how precision oncology breaks through that wall using deep multi-omics mapping (DNA, RNA, immune, and spatial biology), combined with 3D cone-beam interventional oncology to deliver therapy directly inside the pancreatic tumor.
Instead of relying on massive surgeries like the Whipple — with complication rates up to 60% — precision care uses a catheter the size of a hair to deliver genetically targeted chemotherapy, immunotherapy, and nanoparticle-based agents exactly where they are needed. This approach kills the tumor locally and stimulates a systemic immune response throughout the body.
Dr. Prato also explains how microdosed systemic therapy, NK and dendritic cell immunotherapy, phytotherapeutics, and real-time monitoring with ctDNA, CTCs, and methylation scores help treat micrometastatic disease while preserving quality of life.
🎯 What You’ll Learn in This Episode: • Why pancreatic cancer blocks most chemotherapy • How stromal barriers and high-pressure tumors make standard care fail • What 3D cone-beam, catheter-based targeting really looks like • The role of DNA, RNA & immune spatial biology in mapping treatment • How microdosed systemic chemo kills micrometastatic cells with fewer side effects • Why NK cells, dendritic cells & DAMP signaling matter for long-term control • How precision monitoring keeps treatment effective in a fast-mutating cancer
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak to a care coordinator: 866-830-4576
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
The Lyme Lie — How Hidden Infections Sabotage Immunity & Cancer Healing | Dr. Dino Prato
04 mars 2026
00:17:24
This episode discusses the serious implications of Lyme disease, especially cases that remain undiagnosed, highlighting its connection to autoimmune diseases and cancer.
We explore recent research, specifically a 2024 study that found "borrelia burgdorferi" DNA in invasive breast cancer cases, emphasizing the critical need for proper "Lyme disease testing". Understanding the role of the "immune system" and accurate "disease education" is vital for effective "cancer therapy" and overall "health" management.
🎯 What You’ll Learn in This Episode: - Why Lyme disease is frequently missed - What “chronic Lyme disease complex” really means - How co-infections suppress immunity and drive inflammation - The link between infections, autoimmunity, and cancer recurrence - Why false-negative Lyme tests are common - How neuroborreliosis affects the brain and nervous system - Why infections must be treated before repair and recovery - The right questions to ask your doctor about testing
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“You can’t rebuild the immune system until you remove what’s breaking it.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Blood Cancer Recurrence Isn't Treatment Failure—It's This
03 mars 2026
00:11:36
This video explains why blood cancer can recur, often due to minimal residual disease (MRD) that goes undetected despite initial treatment success.
We discuss how initial improvements in scans and blood counts can be misleading, as unseen disease may persist and lead to relapse. Understanding this is crucial for effective blood cancer treatment and preventing future challenges.
🎯 What You’ll Learn in This Episode: - What minimal residual disease really is - Why remission alone isn’t enough in blood cancers - How MRD causes relapse months or years later - The difference between transplant vs short-term immune strike - How borrowed donor immune cells can target MRD - Why timing matters (not for active blast crisis) - How MRD can be tested and monitored - The questions to ask your doctor after remission
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“Relapse doesn’t start big — it starts with what was left behind.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
When Standard Immunotherapy Doesn't Work, Try This Instead
02 mars 2026
00:18:55
In this episode, Dr. Dino Prato navigates the complexities of treating cancers that appear invisible to the immune system, making traditional immunotherapy for cancer less effective.
He explains how building custom immunotherapies and changing tumor information can overcome these limitations, offering new avenues for cancer treatment. This discussion is crucial for anyone interested in advancements in oncology and how precision oncology is shaping the future of care, focusing on immune responses.
🎯 What You’ll Learn in This Episode: - What “cold tumors” really mean - Why KRAS drugs slow cancer but rarely finish it - What microsatellite stability actually tells doctors - Why PD-1 inhibitors fail most patients long-term - How precision oncology turns cold tumors hot - The role of spatial biology and immune mapping - Why direct-to-tumor therapy releases immune targets - The right questions to ask when told “nothing else can be done”
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“Cancer isn’t beaten by managing it — it’s beaten when the immune system can finally see it.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Cancer Patients Are Told to Eat Anything | That's Killing Them
27 févr. 2026
00:12:38
This video clarifies why the common advice to "eat whatever you want" during cancer treatment is misleading, emphasizing that food provides crucial signaling for your body.
We explore how nutrition impacts your immune system, shapes your gut health, and plays a vital role in reducing inflammation and cancer progression. The Mediterranean diet, highlighted by research, offers significant benefits for overall health and fighting cancer, demonstrating how foods that fight cancer can be integrated into a healthy diet.
🎯 What You’ll Learn in This Episode: - Why food acts as immune and metabolic signaling - How the Mediterranean diet supports cancer outcomes - Why gut microbiome diversity matters for immunity - The difference between ancient vs modern Mediterranean diets - Why ultra-processed foods drive inflammation and disease - How to build a sustainable, lifelong anti-cancer diet - How to combine Mediterranean eating with fasting strategies - Practical food examples that support immunity and energy
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“Food is your first immune therapy — if you choose it wisely.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Squamous Cell Carcinoma of the Tongue, Head, and Neck Cancer | Dr. Dino Prato
26 févr. 2026
00:12:29
Dave Coulier, known for his role as Uncle Joey, shares his public battle with oral cancer. His journey included 35 rounds of radiation oncology and robotic surgeon, highlighting how outdated care can be even for those with access to top hospitals.
Our aim is to help patients in their cancer treatment and maintain remission, focusing on effective strategies for head and neck cancer.
🎯 What You’ll Learn in This Episode: - What squamous cell carcinoma of the tongue is - Why head and neck radiation can affect quality of life - The potential immune links between lymphoma and other cancers - How viral infections relate to immune suppression - What deep multi-omics testing reveals - How precision immunotherapy differs from standard protocols - Why early adaptive monitoring matters - Questions to ask before starting treatment
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“Cancer treatment should not only aim for survival — but preserve the life you’re living.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Anktiva | Cancer Immune Stimulation Isn't Enough Without This?
25 févr. 2026
00:21:19
Anktiva is an exciting new cancer immunotherapy that helps the immune system fight and kill cancer cells. Doctors believe it could support treatment for many cancers when used in the right personalized combinations — but what is it really, and why won’t it work the same way for every patient?
In this episode of Outsmart Cancer, Dr. Dino Prato breaks down the science, the hype, and the clinical reality behind Anktiva, an FDA-approved IL-15 super agonist cytokine currently indicated for invasive bladder cancer.
Unlike many targeted cancer drugs that only slow disease, Anktiva is designed to activate the immune system — particularly natural killer cells and CD8 T cells — with the goal of cytotoxic tumor kill. But immune stimulation alone is not enough.
Dr. Prato explains why immunotherapies like Anktiva require the right tumor information to be effective. Without exposing tumor antigens, neoantigens, and damage-associated molecular patterns (DAMPs), even powerful immune activators may produce only short-term responses.
This episode explores how precision oncology integrates deep DNA sequencing, RNA transcriptomics, immune profiling, and spatial biology to identify the right patients, pathways, and combinations. Dr. Prato outlines how direct-to-tumor strategies, micro-dosing, off-label use, and immune-supportive phytotherapeutics can transform Anktiva from a single drug into part of a coordinated immune attack.
🎯 What You’ll Learn in This Episode: - What Anktiva is and how IL-15 immunotherapy works - Why immune stimulation alone doesn’t guarantee success - The role of NK cells, CD8 T cells, and immune memory - Why tumor information must be released for immunotherapy to work - How precision testing guides on- and off-label use - Why plasma exchange may be necessary during strong immune responses - How combination strategies outperform single-agent therapy
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Can Cancer Spread From a Biopsy? Here's What Research Says
24 févr. 2026
00:11:23
This video addresses a common patient fear: whether a biopsy might lead to cancer spread.
We provide honest data and health education, explaining that while biopsy-related seeding is real, the information gained through procedures like lung biopsies is critical for early detection and treatment. Our aim is to empower you with health tips to make informed decisions without hype or false reassurances.
🎯 What You’ll Learn in This Episode: - Whether biopsies can really spread cancer - How rare biopsy-related seeding actually is - Why technique matters more than the needle - What the coaxial needle technique is and why it’s safer - The role of liquid biopsies and circulating tumor cells - When biopsy risk is already irrelevant due to existing spread - Why deep molecular and immune testing matters more than fear - The right questions to ask before agreeing to a biopsy
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“Good data saves lives. Fear delays answers.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
It is now believed that the average person carries the equivalent of a spoonful of microplastics inside their body — with emerging research suggesting significant accumulation in organs such as the brain.
Yet despite growing scientific concern, microplastics remain largely ignored in conventional cancer care.
In this episode of Outsmart Cancer, Dr. Dino Prato explains how microplastics function as invisible internal contaminants that drive chronic inflammation, oxidative stress, immune suppression, and genetic instability — all of which create conditions that allow cancer to grow, spread, and resist treatment.
Dr. Prato explores how microplastics interfere with tumor-suppressive pathways such as p53 and NF-kappa B, disrupt hormonal signaling, and overload detoxification systems — weakening immune surveillance and reducing the effectiveness of chemotherapy, immunotherapy, and targeted treatments.
Because complete avoidance is impossible in a plastic-saturated world, this episode explains why reducing total toxic burden is essential for healing. Dr. Prato outlines the only clinically applied method currently available to help remove microplastics, heavy metals, and inflammatory signaling from the bloodstream, allowing immune function to recover and cancer therapies to work more effectively.
🎯 What You’ll Learn in This Episode:
How microplastics accumulate inside human tissue
Why microplastics act as toxin carriers, not passive particles
The link between chronic inflammation, immune suppression, and cancer
How microplastics interfere with p53, apoptosis, and tumor control
Why toxic load increases treatment resistance and side effects
Why detoxification must accompany cancer therapy
How selective plasma exchange can reduce inflammatory burden
Practical steps to minimize ongoing microplastic exposure
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Your Immune System Is Under Attack — Here's Why Your Cancer Won't Go Away
20 févr. 2026
00:12:41
What if your cancer didn’t begin as bad luck in your DNA — but was fueled by hidden infections your doctors never tested for?
In this episode of Outsmart Cancer, Dr. Dino Prato explains how chronic, undiagnosed infections can weaken the immune system, drive inflammation, disrupt tumor-suppressor pathways, and make cancer more aggressive and resistant to treatment.
While global estimates suggest about 13% of cancers are linked to infections, Dr. Prato’s clinical experience over more than 25 years shows the number may be far higher — largely because most patients are never thoroughly tested. Viruses, bacteria, parasites, mold toxins, and tick-borne infections can persist silently in the body, suppressing immunity long before cancer develops.
Dr. Prato breaks down the three primary ways infections contribute to cancer: direct oncogenic interference with tumor-suppressor genes like p53, genomic instability caused by viral integration, and chronic inflammation that fuels tumor growth and immune exhaustion. He also explains how infections disrupt mitochondrial signaling, impair natural killer cell function, and interfere with modern treatments — including immunotherapy.
This episode highlights why eliminating infections and restoring immune function must be part of precision oncology. Without addressing these hidden drivers, even the most advanced cancer therapies may fail to reach their full effectiveness.
🎯 What You’ll Learn in This Episode:
Why infections are an overlooked contributor to cancer
How viruses like HPV, EBV, and hepatitis affect tumor-suppressor genes
The role of chronic inflammation and immune exhaustion
Why infections increase treatment resistance and immune evasion
How mitochondrial dysfunction impacts cancer immunity
Why deep infectious disease testing is essential
How eliminating infections can improve treatment response
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“Cancer treatment works best when the immune system is no longer under attack.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Resistant Cancer Mutations Require This New Strategy
19 févr. 2026
00:13:15
If you’ve been told you have a KRAS mutation — or another so-called “undruggable” cancer gene — you may have been placed on a specialty inhibitor designed to slow the disease. And these drugs can be helpful. But there’s a critical truth most patients are never told:
Most targeted cancer drugs are cytostatic, not cytotoxic. They slow cancer down — they don’t eliminate it.
In this episode of Outsmart Cancer, Dr. Dino Prato explains why drugs targeting KRAS, BRAF, EGFR, MET, HER2, and similar pathways often create a temporary “honeymoon period.” Like unplugging a Christmas tree, the tumors dim — but once the drug stops working, the cancer lights back up.
The key question becomes: What are you doing with the time these drugs buy you?
Dr. Prato walks through how precision oncology uses that window to activate the immune system. By combining full DNA sequencing, RNA transcriptomics, immune spatial biology, and deep pathway mapping, doctors can identify thousands of targets — not just one mutation. This allows precision combinations, off-label strategies, phytotherapeutics, and direct-to-tumor immunotherapy delivery to expose cancer antigens, release DAMPS, and train natural killer and dendritic cells to eliminate disease system-wide.
Instead of waiting for resistance, this approach turns cytostatic slowdown into cytotoxic immune control, even in patients labeled MSS or “not candidates” for standard immunotherapy.
🎯 What You’ll Learn in This Episode: • Why KRAS and similar inhibitors slow cancer but rarely eliminate it • The difference between cytostatic and cytotoxic cancer treatment • Why specialty drugs create a critical treatment window • How RNA transcriptomics reveals escape pathways beyond DNA mutations • Why immune spatial biology is essential for durable response • How direct-to-tumor delivery protects immunity and increases effectiveness • Why PD-1 inhibitors alone are rarely enough • The right questions to ask when your targeted drug stops working
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
This $2 Billion Cancer Discovery Makes Radiation Look Outdated
18 févr. 2026
00:13:51
Something most cancer patients are never told: the radiation plan you receive is often influenced by the machine a hospital owns, not by what’s best for your cancer biology.
Dr. Dino Prato breaks down the radiation wars — and introduces a disruptive technology that may change oncology entirely: ultrasound-based tumor destruction. Data shows that 40–50% of radiation therapy is palliative, meaning it’s designed to slow disease or reduce symptoms rather than eliminate cancer. The real question becomes: what are we doing during that time?
Dr. Prato explains why radiation has long been an adjuvant tool, how hospital economics and reimbursement drive its overuse, and why newer technologies often struggle to gain adoption. He then introduces histotripsy and sonodynamic therapy, which use focused sound waves to “melt” tumors without radiation. This process creates a tumor lysate rich in antigens, neoantigens, and DAMPS — powerful immune signals that can be repurposed into systemic immunotherapy.
Using precision oncology principles — DNA sequencing, RNA transcriptomics, immune profiling, spatial biology, and AI-guided analysis — this lysate can be combined with immunotherapy, phytotherapeutic adjuvants, and nanoparticle delivery to stimulate whole-body immune response, not just local tumor control.
This episode explores why ultrasound-based approaches may replace large portions of radiation oncology in the future, why adoption is slow, and how immune-centric precision care shifts cancer treatment from palliative delay to strategic immune activation.
🎯 What You’ll Learn in This Episode: • Why 40–50% of radiation therapy is palliative • How hospital ownership influences radiation decisions • The difference between radiation destruction and immune training • What histotripsy and sonodynamic therapy are • How tumor lysate becomes immunotherapy • Why ultrasound avoids many radiation side effects • How precision oncology integrates sound, data, and immunity • Why disruptive cancer technology takes years to reach patients
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Why do some cancer patients relapse even after surgery, chemo, and radiation — while others recover long-term?
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, explains the missing link most oncologists never talk about: DAMPS — Damage Associated Molecular Patterns. These are the danger signals cancer cells release when they die, and they determine whether your immune system wakes up… or whether the cancer becomes more resistant.
You’ll learn why too much chemotherapy or radiation can release uncontrolled DAMPS, triggering inflammation, mutations, and relapse — especially in late-stage disease. And you’ll discover how microdosed, genetically targeted chemotherapy, combined with immune profiling and spatial biology, activates DAMPS in the right way to train your immune system for long-term control.
Dr. Prato walks through how adaptive monitoring (CTCs, ctDNA, methylation), nutritional changes, sleep, inflammation control, phytotherapy, and cellular biologics all work together to keep immune signals tuned and prevent relapse.
🎯 What You’ll Learn in This Episode: • What DAMPS are — and why they determine relapse or recovery • How high-dose chemo/radiation can trigger resistance and mutations • Why microdosed, targeted chemotherapy activates the “right” immune signals • How NK cells, dendritic cells & immune profiling enhance DAMPS response • How sleep, diet, inflammation markers, and stress impact immune signaling • Why liquid biopsies (CTCs, ctDNA, methylation) reveal relapse early • How personalized dosing prevents overactivation and immune collapse • Why the future of cancer care is immune-centric precision oncology
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak to a care coordinator: 866-830-4576
“When you align treatment with immune signaling, you stop fighting cancer — you teach your body to win.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
The $100 Billion Cancer Industry Missed This One Thing
13 févr. 2026
00:12:13
What if the best cancer treatment for you can’t be mass-produced? What if the drug, dose, pathway targets, and delivery route all have to be custom-designed from the ground up — not because it's luxurious, but because it’s necessary?
In this episode of Outsmart Cancer, Dr. Dino Prato explains why true precision oncology is fundamentally different from standard cancer care. Inspired by the St. Jude model for rare pediatric cancers, Dr. Prato reveals why adults with heterogeneous tumors also need custom-built therapies created from DNA sequencing, RNA transcriptomics, immune spatial biology, and real-time monitoring.
Instead of relying on one-size-fits-all guidelines and limited FDA-approved drugs, N-of-1 oncology builds a personalized playbook using on-label, off-label, repurposed drugs, phytotherapeutics, and cellular biologics — all designed around each patient’s unique molecular drivers. This ecosystem includes custom drug compounding, microdosed combination therapy, direct-to-tumor delivery, and immune rebuilding through NK and dendritic cell biologics.
🎯 What You’ll Learn in This Episode: • Why standard care cannot treat today’s heterogeneous, complex cancers • How St. Jude’s precision model inspired Envita’s N-of-1 adult ecosystem • How DNA, RNA, and spatial biology testing reveal thousands of unique targets • Why custom-built drugs and phytotherapeutics outperform off-the-shelf options • How cellular biologics (NK & dendritic cells) rebuild immune killing • Why direct-to-tumor delivery beats systemic chemotherapy for many patients • What real-time monitoring (CTCs, methylation, ctDNA) reveals long before imaging
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak to a care coordinator: 866-830-4576
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Cold Tumors vs Hot Tumors | Why Your Immune System Stops Working
12 févr. 2026
00:10:17
Your body is a city — and your immune system is its army. Every day, it stops thousands of threats without you ever knowing. But when cancer learns to hide behind fake ID badges, jam the “radio signals,” or build stromal barriers, the immune system can lose its ability to see the enemy.
In this powerful episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, uses storytelling to explain exactly how the immune system works — and how cancer escapes detection. From neutrophils and macrophages to dendritic detectives, natural killer cells, and T-cell commanders, you’ll discover what makes your inner army strong… and what causes it to break down.
Dr. Prato also shows how deep immune profiling, DNA/RNA sequencing, and spatial biology help rebuild the immune system through targeted, immune-centric cancer care. By restoring the body’s natural defenses, patients can turn “cold tumors hot” and achieve more durable, long-term control.
🎯 What You’ll Learn in This Episode: • How NK cells, T cells, dendritic cells, and macrophages really work • Why cancer hides using fake ID, checkpoints, and stromal barriers • How toxins, infections, and heavy metals weaken the immune system • Why PD-1 inhibitors often fail without full immune-system repair • The 8-step immune kill loop — and how cancer breaks it • How deep mapping restores immune visibility and targeting
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak to a care coordinator: 866-830-4576
“Your immune system isn’t weak — it’s misdirected. Precision helps it see clearly again.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Insulin Peptide Cancer Treatment IPT: Truth vs Fiction
11 févr. 2026
00:10:20
What if the goal of cancer treatment wasn’t more drug — but smarter delivery?
In this episode of Outsmart Cancer, Dr. Dino Prato explains how peptides and metabolic primers can dramatically improve the effectiveness of precision oncology when used correctly. Drawing from more than 25 years of clinical experience, Dr. Prato walks through the evolution from early insulin potentiation therapy (IPT) to today’s genetically targeted fractionated chemotherapy (GTFC) — a data-driven, immune-centric approach built on deep molecular mapping.
You’ll learn why insulin is not a treatment on its own, but a primer that can temporarily increase tumor uptake of microdosed chemotherapy — only when specific biomarkers are present. Dr. Prato explains how most chemotherapy misses the tumor entirely, and how metabolic primers like insulin, fasting windows, oxygenation, and redox modulation can shift that equation while protecting the immune system.
This episode breaks down how DNA sequencing, RNA transcriptomics, immune profiling, and spatial biology are used to select the right drugs first — and only then decide whether a primer like insulin makes sense. When combined correctly, this strategy promotes immunogenic cell death (DAMPS), trains dendritic cells and NK cells, and supports long-term immune control rather than short-term tumor suppression.
This is not alternative therapy. It’s precision delivery, immune intelligence, and metabolic strategy working together.
🎯 What You’ll Learn in This Episode: • Why insulin is a peptide primer — not a cancer treatment • How early insulin potentiation evolved into modern GTFC • Why most chemotherapy never reaches the tumor • How fasting and metabolic preparation improve drug tolerance • What DAMPS are and why immune signaling determines long-term outcomes • When insulin, oxygen, or inflammatory primers are appropriate — and when they’re not • Why deep DNA, RNA, and immune mapping must come first • How microdosed therapy strengthens immunity instead of destroying it
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“Precision isn’t about adding more — it’s about delivering smarter.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Can Immunotherapy REALLY Save Your Life with Melanoma?
10 févr. 2026
00:09:07
What is the best treatment for advanced melanoma — and why do some therapies fail while others succeed?
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, breaks down the future of melanoma care: deep mapping and immune-centered precision oncology. Using DNA, RNA, and spatial biology, Dr. Prato explains how mapping every pathway — not just BRAF mutations — gives doctors a full picture of the tumor’s environment, revealing why PD-1 inhibitors, BRAF/MEK drugs, and other standard therapies work for only a small group of patients.
The key to melanoma, he says, lies in natural killer (NK) cells. These immune cells, trained through AAIT (Autologous Adoptive Immunotherapy), can cross the blood-brain barrier and destroy tumor cells without the side effects of high-dose systemic drugs. By combining deep mapping, immune retraining, and microdosed precision therapies, Envita helps patients move from reactionary care to immune-guided treatment.
🎯 What You’ll Learn in This Episode: • Why most standard melanoma treatments only help a small percentage of patients • How DNA, RNA, and spatial biology mapping reveal hidden resistance pathways • The difference between TIL therapy and AAIT (Autoglutid Adaptive Immunotherapy) • How NK and dendritic cells are trained using DAMPs to target melanoma cells • Why changing the tumor microenvironment is critical for immune response • How AAIT avoids cytokine storms and side effects seen in other therapies
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
The history of cancer treatment is not the clean, linear story most of us were taught. It’s a story of brilliant pioneers, fierce resistance, political power, money, and ideas that were once ridiculed — only to later become foundations of modern medicine.
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, lifts the veil on the forgotten innovators who helped shape today’s precision oncology. From Samuel Hahnemann’s focus on individualized care, to Otto Warburg’s metabolic discoveries, to Judah Folkman’s angiogenesis theory and Steven Rosenberg’s early immunotherapy breakthroughs — many of today’s “standard” ideas were once mocked, suppressed, or criminalized.
Dr. Prato walks through how the Flexner Report and the rise of pharmaceutical-driven medicine narrowed the focus of healthcare, sidelining nutrition, metabolism, immune intelligence, and personalization. At the same time, figures like Palmer, Still, Lust, Ravici, Nieper, Gerson, and others pushed boundaries — sometimes too far, sometimes imperfectly — but often planting seeds that modern science later validated.
The episode culminates in the Hallmarks of Cancer, the framework that finally unified genetics, metabolism, angiogenesis, and immune evasion — and paved the way for today’s N-of-1, data-driven precision oncology, powered by DNA sequencing, RNA transcriptomics, immune profiling, spatial biology, and AI-guided decision-making.
🎯 What You’ll Learn in This Episode: • Why many breakthrough cancer ideas were once ridiculed or suppressed • How money, patents, and power shaped modern oncology • The origins of metabolic, immune, and angiogenesis-based cancer therapies • Why nutrition, lifestyle, and metabolism were removed from medical training • How the Hallmarks of Cancer unified decades of competing theories • Why cancer is heterogeneous and cannot be treated one-size-fits-all • How N-of-1 precision oncology replaces dogma with data • Why humility, curiosity, and testing matter more than ideology
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“Progress doesn’t come from defending dogma — it comes from letting the data lead.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Complete Remission Without Chemo | The Immune-Centric Approach That Works
05 févr. 2026
00:06:35
When Fran was diagnosed with metastatic non-small cell lung cancer with brain metastases, she was offered one option: palliative radiation and more chemotherapy. She said no. Not because she gave up — but because she wanted a plan built for her, not a one-size-fits-all protocol.
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, shares how precision oncology and immune-centric care helped Fran achieve a complete response — without traditional chemotherapy. Lung cancer is one of the most immunogenic cancers, yet standard immunotherapy often fails long-term because it isn’t properly targeted.
Dr. Prato explains how deep multi-omics mapping — including DNA sequencing, RNA transcriptomics, and immune spatial biology — revealed the exact immune targets needed to design Fran’s treatment. Using genetically targeted fractionated chemotherapy, custom-built immunotherapy, and autologous NK and dendritic cell therapies matched to her DAMPS, the immune system was trained to recognize and eliminate cancer throughout the body — including across the blood–brain barrier.
Instead of exhausting the immune system with high-dose chemo or palliative radiation, this approach focused on immunogenic cell death, real-time liquid biopsy monitoring, metabolic support, and precision drug selection (on-label, off-label, repurposed, and phytotherapeutic). The result: tumor clearance, restored energy, and durable immune control.
🎯 What You’ll Learn in This Episode: • Why lung cancer is highly responsive to immunotherapy — when targeted correctly • Why PD-1 inhibitors often fail without immune spatial biology • How DAMPS guide immune training and immunogenic cell death • The role of NK cells and dendritic cells in clearing metastatic disease • How microdosed, targeted chemo reaches the brain without severe toxicity • Why DNA alone isn’t enough — and RNA + immune mapping change everything • How liquid biopsies (CTCs, ctDNA, methylation) monitor remission early • Why precision oncology replaces “step therapy” with a custom playbook
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“Refusing chemo doesn’t mean refusing hope — it means choosing precision.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Can Our BODY'S Natural Healing Power FIGHT Cancer With Cell Vaccines?
04 févr. 2026
00:16:00
What if the most powerful cancer treatment isn’t a drug — but your own body?
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, challenges the war-based model of oncology and explains why the immune system is the most important anti-cancer weapon we have. Long before chemotherapy and radiation existed, the body was already eliminating early cancer cells thousands of times a day. When cancer takes hold, it’s not because the immune system disappeared — it’s because it was misdirected, suppressed, or never given the right information.
Dr. Prato walks through the uncomfortable history of chemotherapy and radiation, their origins in warfare, and why a “kill at any cost” strategy often damages the very system needed for long-term recovery. He explains how precision oncology, N-of-1 care, and immune-centered strategies focus on restoring the body’s terrain, correcting root causes, and retraining natural killer cells and dendritic cells to recognize and eliminate cancer.
From chronic inflammation, infections, toxins, stress, and poor sleep to immune exhaustion caused by aggressive treatments, this episode connects the dots between biology, terrain, and healing. It also introduces how AAIT (autologous adaptive immunotherapy), deep multi-omics mapping, targeted microdosing, nutrition, gut health, and lifestyle restoration work together to support durable immune function and better outcomes.
🎯 What You’ll Learn in This Episode: • Why the immune system is the most important anti-cancer therapy • How NK cells and dendritic cells work together to eliminate cancer • Why high-dose chemo and radiation often weaken immune surveillance • What DAMPS are and how the right signals activate immune killing • How toxins, infections, stress, and poor sleep suppress immunity • Why N-of-1 precision oncology replaces one-size-fits-all treatment • The key questions every patient should ask their oncologist • How diet, gut health, faith, and mindset influence immune resilience
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
What if a PERSONALIZED Cancer Plan Could Change Everything?
03 févr. 2026
00:14:35
Most cancer care still treats populations — not people.
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, introduces OncoMeta, a revolutionary precision ecosystem that designs custom cancer treatment programs based entirely on each patient’s unique biology. Instead of guessing, OncoMeta maps your DNA, RNA, and immune spatial biology to reveal every cancer driver and immune blockade — then builds personalized medications, delivery systems, and immune retraining therapies around it.
This next-generation model moves beyond standard “one-size-fits-all” guidelines to a fully integrated system combining molecular mapping, targeted microdosing, and immune activation. The result: smarter drug delivery, fewer side effects, and higher response rates.
🎯 What You’ll Learn in This Episode: • Why standard cancer treatments fail to account for immune terrain and tumor microenvironments • How OncoMeta integrates DNA, RNA, and immune spatial biology for deep targeting • The role of precision mapping in designing microdosed, immune-centered therapies • Why less chemo, given precisely, often delivers better results • How interventional oncology delivers medication directly to the tumor site • Why immune-centric care leads to long-term remission and better quality of life
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak to a care coordinator: 866-830-4576
“You don’t need more treatment — you need the right treatment. Precision changes everything.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
How Artificial Intelligence Can Supercharge Your Cancer Treatment
02 févr. 2026
00:09:51
Imagine scanning a tumor like a 3D object — then generating a custom treatment plan built entirely around your biology. That’s generative oncology, the future of cancer care.
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, explains how AI + physician intelligence + multi-omics testing work together to design N-of-1 treatment plans for each patient. Instead of relying on 10–20 markers, generative oncology uses thousands of data points: DNA sequencing, RNA transcriptomics, immune profiling, and spatial biology to build a “heat map” of the cancer’s drivers, resistance pathways, and immune barriers.
With this information, doctors can custom-design targeted therapies — on-label, off-label, repurposed drugs, phytotherapeutics, oxygen therapies, nanoparticles, immune biologics (NK & dendritic cells), and even personalized vaccines. Combined with micro-dosed delivery and interventional oncology, precision care increases targeting while reducing toxicity and improving quality of life.
🎯 What You’ll Learn in This Episode: • What generative oncology is and how it differs from standard care • How DNA, RNA, immune profiling & spatial biology reveal thousands of targets • Why cancer is bimodal — metabolic + mutational — and must be treated that way • How AI helps build custom treatment plans without replacing physicians • Why NK cells, dendritic cells & DAMPS signaling are essential for long-term control • How repurposed drugs and phytotherapeutics are selected through heat-map targeting • How micro-dosed chemo and interventional delivery reduce toxicity • Why precision oncology requires extensive physician training
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
When you hear the words “clinical trial,” you’re told it might be your breakthrough. But what most patients aren’t told is how clinical trials actually work — and what their limitations are.
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, explains the good, the bad, and the uncomfortable truth about cancer clinical trials. Most trials are designed to test one drug against one marker, even though cancer uses dozens of pathways to survive, spread, and resist treatment. Patients with the same cancer and stage often have completely different molecular drivers — yet trials rarely account for that complexity.
Dr. Prato contrasts the traditional trial model with N-of-1 precision oncology, where treatment is custom-built around your biology using deep multi-omics testing: DNA sequencing, RNA transcriptomics, immune profiling, and spatial biology. Instead of slowing cancer temporarily with cytostatic drugs, this approach focuses on immune-centric, cytotoxic strategies designed to expose cancer to the immune system and eliminate it.
You’ll also learn why fewer than 10% of adult cancer patients ever enroll in trials, why many drugs fail late in development, and why maximum-dose testing often creates unnecessary toxicity. Precision oncology flips that model — using the smallest effective dose, the right combinations, and real-time monitoring to improve quality of life and long-term response.
🎯 What You’ll Learn in This Episode: • How cancer clinical trials are designed — and their built-in limitations • Why most new cancer drugs are cytostatic, not cytotoxic • Why two patients with the same cancer rarely need the same treatment • What N-of-1 precision oncology really means • How deep DNA, RNA, immune & spatial testing changes outcomes • Why immune-centric care matters more than one “breakthrough” drug • The right questions to ask before entering a clinical trial
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak with a care coordinator: 866-830-4576
“Clinical trials look for one drug that works for many. Precision oncology builds the right plan for you.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
A Dose of Reality — Inside the Cancer Industry | Dr. Dino Prato Exposes the Truth
29 janv. 2026
00:10:58
Chemotherapy didn’t start in a clinic — it started in a war.
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, pulls back the curtain on the origins of modern oncology and why, 80 years later, the system still relies on the same high-dose, population-based model born from wartime poisons.
From the discovery of mustard gas toxicity in 1942 to today’s billion-dollar chemotherapy industry, Dr. Prato exposes how the “sick care cartel” — pharmaceutical companies, PBMs, and hospital systems — profits from managing cancer rather than curing it. But there’s a new model rising: immune-centric precision oncology.
Dr. Prato explains how deep multi-omics mapping (DNA, RNA, immune, and spatial biology) replaces guesswork with custom-built, low-toxicity treatments that awaken the body’s immune system — turning “maximum tolerated dose” into minimum effective precision.
🎯 What You’ll Learn in This Episode: • The wartime origins of chemotherapy and why that model still drives care today • Why most new cancer drugs only extend life by months on average • How PBMs and hospital markups distort care and inflate costs • The difference between cytostatic and cytotoxic treatments — and why it matters • How microdosed, immune-centric precision care rebuilds the body instead of breaking it • Why DNA/RNA testing and spatial biology are the key to custom-built therapy
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak to a care coordinator: 866-830-4576
“The war on cancer was never meant to end — until precision changed the rules.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Beating Breast Cancer Twice — Why Precision Care Prevents Recurrence
28 janv. 2026
00:16:13
Imagine beating breast cancer — only for it to come back a year later in the other breast.
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, exposes why so many breast cancer patients relapse — and how precision oncology could have prevented it. Standard protocols and limited RNA blood tests often miss key drivers, leaving patients on the wrong medications 90% of the time.
Dr. Prato reveals how Envita’s OncoMeta precision ecosystem uses DNA/RNA sequencing, immune spatial biology, and adaptive monitoring to detect the smallest signs of recurrence before it happens. Instead of another round of toxic chemo and surgery, patients receive custom-designed, microdosed therapies like Genetically Targeted Fractionated Chemotherapy (GTFC), cryoablation, and immune retraining to destroy cancer while preserving strength.
🎯 What You’ll Learn in This Episode: • Why standard testing misses hidden tumor drivers • The critical role of immune typing and spatial biology • How OncoMeta connects testing, drug design, and delivery in one system • Why cryoablation can replace surgery and preserve immune antigens • How circulating tumor cell monitoring prevents relapse early • Why precision care restores health while protecting the immune system
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak to a care coordinator: 866-830-4576
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
What if the best cancer treatment for you can’t be mass-produced? What if the drug, dose, pathway targets, and delivery route all have to be custom-designed from the ground up — not because it's luxurious, but because it’s necessary?
In this episode of Outsmart Cancer, Dr. Dino Prato explains why true precision oncology is fundamentally different from standard cancer care. Inspired by the St. Jude model for rare pediatric cancers, Dr. Prato reveals why adults with heterogeneous tumors also need custom-built therapies created from DNA sequencing, RNA transcriptomics, immune spatial biology, and real-time monitoring.
Instead of relying on one-size-fits-all guidelines and limited FDA-approved drugs, N-of-1 oncology builds a personalized playbook using on-label, off-label, repurposed drugs, phytotherapeutics, and cellular biologics — all designed around each patient’s unique molecular drivers. This ecosystem includes custom drug compounding, microdosed combination therapy, direct-to-tumor delivery, and immune rebuilding through NK and dendritic cell biologics.
🎯 What You’ll Learn in This Episode: • Why standard care cannot treat today’s heterogeneous, complex cancers • How St. Jude’s precision model inspired Envita’s N-of-1 adult ecosystem • How DNA, RNA, and spatial biology testing reveal thousands of unique targets • Why custom-built drugs and phytotherapeutics outperform off-the-shelf options • How cellular biologics (NK & dendritic cells) rebuild immune killing • Why direct-to-tumor delivery beats systemic chemotherapy for many patients • What real-time monitoring (CTCs, methylation, ctDNA) reveals long before imaging
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak to a care coordinator: 866-830-4576
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Cancer Came Back After Clear Scans — Here's What They Missed
26 janv. 2026
00:09:11
“Green lights” don’t always mean you’re cancer-free.
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, shares the story of Marco, a 56-year-old colon cancer patient who thought his clear scans meant remission — until the cancer came back in his liver months later.
Despite surgery, chemo, and even integrative vitamin C therapy, Marco’s testing missed critical early warning signs: circulating tumor cells, methylation scores, and vesicle markers that show metastasis before imaging ever does. Without full multi-omics mapping (DNA, RNA, and spatial biology) and immune profiling, the treatment plan never targeted the real drivers behind his cancer.
Dr. Prato reveals how deep precision mapping and immune-centered therapy rebuilt Marco’s treatment plan — combining microdosed chemotherapy, repurposed drugs, immune retraining (AAIT), and direct-to-tumor delivery to awaken the immune system and bring him to remission.
🎯 What You’ll Learn in This Episode: • Why clear scans can hide microscopic cancer spread • How circulating tumor cell and methylation testing detect recurrence early • The difference between cytostatic and cytotoxic cancer treatments • How cold tumors can be turned “hot” with immune activation • Why microdosed chemo and DAMP signaling strengthen immune response • How AAIT uses NK and dendritic cells to sustain remission
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak to a care coordinator: 866-830-4576
“Don’t mistake remission for resolution — precision data makes all the difference.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Gut Microbiome WARRIORS - Fighting Cancer Naturally
23 janv. 2026
00:15:29
If 70% of your immune system lives in your gut, then your microbiome may be one of the most powerful tools you have in your cancer journey.
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, explains why the gut lining — packed with immune cells, microbes, and signaling pathways — determines how well you respond to chemotherapy, immunotherapy, and precision-built biologics.
You’ll learn how chemotherapy, toxins, processed foods, and chronic inflammation disrupt the gut wall, lowering microbial diversity and weakening the immune system. Dr. Prato also highlights key species like Akkermansia and Bifidobacteria, which repeatedly show up in research as strong predictors of immunotherapy success.
Discover how resistant starches, fermented foods, polyphenols, healthy fats, and superfoods — combined with targeted prebiotics, probiotics, and beta-glucans — help rebuild the gut ecosystem. Small, gradual changes can restore microbial diversity, reduce inflammatory cytokines, improve NK and dendritic cell activity, and strengthen overall immunity.
🎯 What You’ll Learn in This Episode: • Why 70–80% of immune cells live in the gut • How microbiome diversity predicts immunotherapy response • The impact of chemotherapy-induced dysbiosis on immunity • Best foods to rebuild the gut: fermented foods, resistant starches, polyphenols • Why Akkermansia & Bifidobacteria matter for anti-tumor immunity • How to lower inflammation, improve gut lining repair, and boost NK cells • Why slow dietary changes beat extreme shifts for long-term gut healing
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak to a care coordinator: 866-830-4576
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
What's the BIGGEST Breakthrough in Precision Era Pancreatic Cancer TREATMENT?
22 janv. 2026
00:14:03
Pancreatic cancer is one of the toughest cancers in the world — not just because of its location, but because of the stromal barriers that block chemotherapy from reaching the tumor. Most IV chemo delivers less than 1% of the drug to the cancer itself. The result: months of toxicity with very little benefit.
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, explains how precision oncology breaks through that wall using deep multi-omics mapping (DNA, RNA, immune, and spatial biology), combined with 3D cone-beam interventional oncology to deliver therapy directly inside the pancreatic tumor.
Instead of relying on massive surgeries like the Whipple — with complication rates up to 60% — precision care uses a catheter the size of a hair to deliver genetically targeted chemotherapy, immunotherapy, and nanoparticle-based agents exactly where they are needed. This approach kills the tumor locally and stimulates a systemic immune response throughout the body.
Dr. Prato also explains how microdosed systemic therapy, NK and dendritic cell immunotherapy, phytotherapeutics, and real-time monitoring with ctDNA, CTCs, and methylation scores help treat micrometastatic disease while preserving quality of life.
🎯 What You’ll Learn in This Episode: • Why pancreatic cancer blocks most chemotherapy • How stromal barriers and high-pressure tumors make standard care fail • What 3D cone-beam, catheter-based targeting really looks like • The role of DNA, RNA & immune spatial biology in mapping treatment • How microdosed systemic chemo kills micrometastatic cells with fewer side effects • Why NK cells, dendritic cells & DAMP signaling matter for long-term control • How precision monitoring keeps treatment effective in a fast-mutating cancer
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak to a care coordinator: 866-830-4576
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
What Most Cancer Patients Don’t Know — Why Precision Targeting Changes Everything
21 janv. 2026
00:09:37
Most cancer patients never hear the truth: access to care doesn’t mean access to the best care.
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, breaks down why standard cancer treatment often fails to deliver long-term results. Built around population averages, insurance billing, and hospital revenue models — not the patient — most protocols overlook the thousands of genetic and immune markers that determine how your body responds to treatment.
Dr. Prato explains how multi-omics deep mapping (DNA, RNA, immune, and spatial biology) reveals the true drivers of your cancer and how immune-centric, precision-built care can transform outcomes. This episode dives into how Envita’s precision ecosystem custom-builds drug combinations, delivery systems, and immune retraining to help patients achieve durable remission — not just short-term control.
🎯 What You’ll Learn in This Episode: • Why standard of care treats population averages, not individuals • How multi-omics testing (DNA, RNA, immune, spatial biology) changes treatment outcomes • The difference between cytostatic (slowing) and cytotoxic (killing) therapies • How immune-centric care “turns cold tumors hot” for better response • Why adaptive real-time monitoring helps prevent relapse • The key questions every cancer patient should ask before starting treatment
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak to a care coordinator: 866-830-4576
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Stage IV Breast Cancer Remission — The Power of Precision Oncology | Dr. Dino Prato
20 janv. 2026
00:11:58
She was 67, a grandmother, diagnosed with Stage IV ER/PR-positive, HER2-negative breast cancer — with metastases through her bones. Standard chemotherapy left her devastated: fatigue, nausea, hair loss, neuropathy, and no lasting results. She vowed never again.
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, shares how precision oncology changed everything. Using deep mapping (DNA, RNA, immune, and spatial biology), his team discovered blocked immune pathways and stromal barriers — the “walls” preventing chemo and immune cells from reaching the cancer.
Through genetically targeted fractionated chemotherapy (GTF), image-guided interventional oncology, and immune retraining with NK and dendritic cells, this grandmother achieved what she wanted most — real healing without the suffering. In 14 weeks, bone pain was gone, energy returned, and her life reignited.
🎯 What You’ll Learn in This Episode: • Why HER2-negative, hormone-resistant breast cancers are harder to treat • How deep DNA/RNA mapping finds hidden resistance pathways • What stromal barriers are — and how to break them • How microdosed chemo and direct tumor delivery reduce toxicity • Why immune retraining helps achieve lasting remission • The six essential questions every cancer patient should ask their doctor
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak to a care coordinator: 866-830-4576
“This wasn’t luck — it was precision. And precision changes everything.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
What are the BEST Options for Brain Cancer GBM Treatment Today?
19 janv. 2026
00:12:16
Glioblastoma multiforme (GBM) is one of the hardest cancers in the world to treat — not just because it grows fast, but because it spreads like hidden tentacles throughout the brain and hides behind the blood–brain barrier.
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, explains why GBM keeps coming back even after surgery, radiation, and temozolomide — and how deep multi-omics mapping, smart drug delivery, and immune-centric therapy can change the fight. Using the story of a patient we’ll call Tom, Dr. Prato breaks down how DNA sequencing, RNA transcriptomics, immune spatial biology, and targeted immunotherapy work together to overcome resistance, penetrate the blood–brain barrier, and awaken the body’s natural killer cells.
You’ll learn how strategies like genetically targeted fractionated chemotherapy (GTF), AAIT cellular biologics, oncolytic viruses, methylene blue mitochondrial support, and phytotherapeutics help turn a cold, invisible GBM into a hot, immune-responsive target — all while improving quality of life and real-time monitoring with CTCs and methylation scores.
🎯 What You’ll Learn in This Episode: • Why GBM returns even after surgery, radiation & temozolomide • How DNA, RNA & immune spatial biology reveal hidden tumor pathways • Why the blood–brain barrier blocks many standard drugs • How microdosed, genetically targeted chemo activates DAMP signaling • The role of NK cells, dendritic cells & AAIT in immune-centric GBM care • How mitochondrial repair (cytochrome C, methylene blue, vitamin C) restores apoptosis • Why gut health plays a critical role in brain-immune function
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak to a care coordinator: 866-830-4576
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Your body is a city — and your immune system is its army. Every day, it stops thousands of threats without you ever knowing. But when cancer learns to hide behind fake ID badges, jam the “radio signals,” or build stromal barriers, the immune system can lose its ability to see the enemy.
In this powerful episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, uses storytelling to explain exactly how the immune system works — and how cancer escapes detection. From neutrophils and macrophages to dendritic detectives, natural killer cells, and T-cell commanders, you’ll discover what makes your inner army strong… and what causes it to break down.
Dr. Prato also shows how deep immune profiling, DNA/RNA sequencing, and spatial biology help rebuild the immune system through targeted, immune-centric cancer care. By restoring the body’s natural defenses, patients can turn “cold tumors hot” and achieve more durable, long-term control.
🎯 What You’ll Learn in This Episode: • How NK cells, T cells, dendritic cells, and macrophages really work • Why cancer hides using fake ID, checkpoints, and stromal barriers • How toxins, infections, and heavy metals weaken the immune system • Why PD-1 inhibitors often fail without full immune-system repair • The 8-step immune kill loop — and how cancer breaks it • How deep mapping restores immune visibility and targeting
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak to a care coordinator: 866-830-4576
“Your immune system isn’t weak — it’s misdirected. Precision helps it see clearly again.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Kill Cancer With PRECISION Immune System Uprising - Story of King Tumor
15 janv. 2026
00:09:14
Once upon a time, there was a peaceful village — until King Tumor arrived.
In this unique Outsmart Cancer episode, Dr. Dino Prato, founder of Envita Medical Centers, tells a bedtime story that reveals the truth about how cancer really grows — and how precision oncology gives the body the power to fight back. Through the story of a cruel king and a brave village, Dr. Prato illustrates how traditional treatments like surgery and high-dose chemotherapy often cause collateral damage, while precision care uses “small teams” — microdosed, targeted, and immune-guided treatments — to rebuild the body’s natural defenses.
Using DNA/RNA sequencing, immune profiling, and spatial biology, Envita’s approach maps the entire “kingdom” of cancer, identifying the roads, fortresses, and hiding places where cancer lives — then delivers customized therapies directly to those targets.
🎯 What You’ll Learn in This Episode: • Why surgery and high-dose chemo often miss the real targets • How immune mapping and precision targeting strengthen the body’s defenses • The role of microdosed, genetically targeted chemo in activating immunity • How DAMP signaling turns immune cells into “soldiers” that seek and destroy cancer • Why precision oncology rebuilds health instead of breaking it down • How “teaching the villagers” — your immune system — keeps cancer from returning
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak to a care coordinator: 866-830-4576
“The immune system isn’t weak — it’s just been misdirected. Precision turns it back into your greatest weapon.”
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
Why Prostate Surgery Wasn’t the Cure | Dr. Dino Prato
14 janv. 2026
00:09:54
He had his prostate removed by a robot. “All clear,” they said. Years later, his PSA started rising again. If the prostate was gone — how could the cancer be back?
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, tells the story of Frank, a 59-year-old patient who underwent robotic-assisted prostatectomy believing it was the cure. But when his PSA began climbing, he discovered what most men never hear: surgery removes tissue, not necessarily the cancer or its root causes.
Dr. Prato explains how deep mapping (DNA, RNA, and immune spatial biology) can detect micro-metastases long before imaging or PSA changes. He reveals why circulating tumor cells (CTCs) and methylation testing are critical for detecting early spread — and how interventional oncology and custom immunotherapy can eliminate cancer without the devastating side effects of repeat surgeries or radiation.
🎯 What You’ll Learn in This Episode: • Why prostate surgery often fails to eliminate micro-metastatic cancer • How CTCs and methylation testing detect recurrence earlier than PSA • What deep mapping and spatial biology reveal about hidden resistance • How interventional oncology targets tumors without harming healthy tissue • Why immunotherapy and NK cells are crucial for durable remission • How adaptive monitoring keeps cancer in check long-term
📍 Envita Medical Centers – Scottsdale, AZ 🌐 Learn more: www.envita.com 📞 Speak to a care coordinator: 866-830-4576
Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied. ________________________________________ Outcomes Disclaimer The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.